Bempedoic acid in the current era of lipid management

Chirde, Satish Rameshrao (2025) Bempedoic acid in the current era of lipid management. World Journal of Advanced Research and Reviews, 26 (1). pp. 3908-3913. ISSN 2581-9615

Bempedoic acid, a first-in-class adenosine triphosphate-citrate lyase inhibitor, significantly advances lipid management. This review examines the clinical evidence, efficacy, and safety profile of bempedoic acid based on major clinical trials and recent meta-analyses. The CLEAR trials program demonstrated significant low density lipoprotein cholesterol (LDL-C) reductions ranging from 17-28.5% across different patient populations, with the CLEAR outcomes trial showing a 13% reduction in major adverse cardiovascular events. Meta-analyses have confirmed these findings, showing consistent LDL-C reductions and cardiovascular benefits, particularly in statin-intolerant patients. The medication's unique liver-specific activation mechanism contributes to reduced muscle-related side effects compared to statins. Current guidelines from both the American College of Cardiology and the European Society of Cardiology position bempedoic acid as a valuable option for high-risk patients requiring additional LDL-C lowering, especially those who are statin-intolerant or unable to achieve goals with maximally tolerated statin therapy. Bempedoic acid demonstrates a generally favourable safety profile, monitoring is recommended for potential adverse effects including elevated uric acid levels and liver enzymes.